| Name | Title | Contact Details |
|---|
Apollo MarCom is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Chester River Health System is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Chestertown, MD. To find more information about Chester River Health System, please visit www.chesterriverhealth.org
Symbion Research International is a Agoura Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Harvard Pilgrim Health Care is a full-service health benefits company serving more than one million members throughout Massachusetts, New Hampshire, Maine, Connecticut, and beyond. We`re dedicated to improving the quality and value of health care for the people and communities we serve. We recognize that health care is not one size fits all, and we`re working every day to create value for our members by respecting their unique values, languages, and cultures. For more than 40 years, we have built a reputation for exceptional clinical quality, preventive care, disease management, and member satisfaction, and have consistently been rated among the top plans in the country. In 2013 Harvard Pilgrim Health Care was ranked #1 private health plan in America for the 10th consecutive year. (#1 plan information available at http://countusin.harvardpilgrim.org/privacy) An independent, not-for-profit organization known for innovation that delivers better health and cost management, Harvard Pilgrim offers a wide variety of health insurance options for companies, families, and individuals. Our fully-insured and self-insured PPO, POS, and HMO plans are available with multiple variations tailored to the needs of our members and their employers. So, wherever, whenever you are looking for a partner in health benefits, or a great place to work, count us in. Harvard Pilgrim Health Care includes Harvard Pilgrim Health Care, Harvard Pilgrim Health Care of New England, and HPHC Insurance Company.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.